RELMADA THERAPEUTICS, INC.RLMDEarnings & Financial Report
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
Revenue
$1.3M
Gross Profit
N/A
Operating Profit
$-22.7M
Net Profit
$-22.0M
Gross Margin
N/A
Operating Margin
-1717.3%
Net Margin
-1665.0%
YoY Growth
59.7%
EPS
$-0.73
RELMADA THERAPEUTICS, INC. Q3 FY2023 Financial Summary
RELMADA THERAPEUTICS, INC. reported revenue of $1.3M (up 59.7% YoY) for Q3 FY2023, with a net profit of $-22.0M (up 44.2% YoY) (-1665.0% margin).
Key Financial Metrics
| Total Revenue | $1.3M |
|---|---|
| Net Profit | $-22.0M |
| Gross Margin | N/A |
| Operating Margin | -1717.3% |
| Report Period | Q3 FY2023 |
RELMADA THERAPEUTICS, INC. Annual Revenue by Year
RELMADA THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2023 revenue was $5.2M).
| Year | Annual Revenue |
|---|---|
| 2023 | $5.2M |
| 2022 | $2.7M |
RELMADA THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
RELMADA THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $1.3M | +13.0% | N/A | N/A |
| Q3 FY2023 | $1.3M | +59.7% | $-22.0M | -1665.0% |
| Q2 FY2023 | $1.4M | +252.0% | $-25.3M | -1855.9% |
| Q1 FY2023 | $1.2M | +266.0% | $-26.3M | -2179.6% |
| Q4 FY2022 | $1.1M | +602.5% | $-37.9M | -3404.5% |
| Q3 FY2022 | $827.6K | +178.1% | $-39.4M | -4762.9% |
| Q2 FY2022 | $387.3K | +20.0% | $-39.9M | -10310.2% |
| Q1 FY2022 | $329.9K | -21.4% | $-39.7M | -12046.0% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $329949 | $387333 | $827614 | $1.1M | $1.2M | $1.4M | $1.3M | $1.3M |
| YoY Growth | -21.4% | 20.0% | 178.1% | 602.5% | 266.0% | 252.0% | 59.7% | 13.0% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $225.8M | $215.8M | $187.1M | $152.9M | $135.6M | $122.0M | $109.1M | $97.6M |
| Liabilities | $15.4M | $18.9M | $20.8M | $12.5M | $10.1M | $10.7M | $8.4M | $12.2M |
| Equity | $210.4M | $196.9M | $166.3M | $140.4M | $125.5M | $111.3M | $100.7M | $85.4M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-19.4M | $-21.6M | $-26.9M | $-35.9M | $-16.5M | $-13.3M | $-11.6M | $-10.2M |